Last Updated : January 17, 2025
Details
FilesGeneric Name:
secukinumab
Project Status:
Complete
Therapeutic Area:
Hidradenitis suppurativa
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Call for patient/clinician input open:
Brand Name:
Cosentyx
Project Line:
Reimbursement Review
Project Number:
SR0781-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Cosentyx is indicated for the treatment of adult patients with moderate to severe hidradenitis suppurativa (acne inversa) who have responded inadequately to conventional systemic hidradenitis suppurativa therapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Cosentyx is indicated for the treatment of adult patients
with moderate to severe hidradenitis suppurativa (acne
inversa) who have responded inadequately to conventional
systemic hidradenitis suppurativa therapy.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | March 28, 2023 |
|---|---|
| Call for patient/clinician input closed | May 23, 2023 |
| Clarification: - Patient input submission received from the Canadian Skin Patient Alliance (CSPA), HS Heroes, and Hidradenitis & Me Support Group | |
| Submission received | May 10, 2023 |
| Submission accepted | May 25, 2023 |
| Review initiated | May 26, 2023 |
| Draft CADTH review report(s) provided to sponsor for comment | August 10, 2023 |
| Deadline for sponsors comments | August 21, 2023 |
| CADTH review report(s) and responses to comments provided to sponsor | September 15, 2023 |
| Expert committee meeting (initial) | September 27, 2023 |
| Clarification: - CDEC recommendation held pending receipt of NOC and evaluation of the finalized submission requirements. | |
| Draft recommendation issued to sponsor | August 07, 2024 |
| Clarification: - Submission temporarily suspended - Additional information has been received and the temporary suspension of the review has been lifted | |
| Draft recommendation posted for stakeholder feedback | August 15, 2024 |
| End of feedback period | August 29, 2024 |
| Final recommendation issued to sponsor and drug plans | September 12, 2024 |
| Final recommendation posted | October 01, 2024 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | September 26, 2024 |
| CADTH review report(s) posted | January 17, 2025 |
Files
Last Updated : January 17, 2025